CSTL logo

Castle Biosciences, Inc. (CSTL)

$32.98

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on CSTL

Market cap

$1.02B

EPS

-0.75

P/E ratio

--

Price to sales

2.94

Dividend yield

--

Beta

1.001101

Price on CSTL

Previous close

$32.75

Today's open

$33.35

Day's range

$32.51 - $34.24

52 week range

$17.72 - $44.28

Profile about CSTL

CEO

Derek J. Maetzold

Employees

1002

Headquarters

Friendswood, TX

Exchange

NASDAQ Global Market

Shares outstanding

30818291

Issue type

Common Stock

CSTL industries and sectors

Healthcare

Medical Diagnostics & Screening

News on CSTL

Castle Biosciences Earns 2026 Top Workplaces Awards Recognizing Its People-First Culture

Regional honors in Houston, Arizona and Pittsburgh, national healthcare industry recognition and eight Culture Excellence awards bring Castle's 2026 Top Workplaces honors to 13 FRIENDSWOOD, Texas, Nov. 12, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has earned regional Top Workplaces awards in Houston, Arizona and Pittsburgh, along with national recognition through the Top Workplaces Healthcare Industry award and eight Top Workplaces Culture Excellence awards. Based on employee feedback, these honors reflect Castle's continued commitment to creating a workplace where people feel valued, supported and connected to a shared purpose.

news source

PRNewsWire • Nov 12, 2026

news preview

DecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging

SDPA analysis demonstrates DecisionDx-Melanoma can identify higher-risk patients within a traditionally low-risk population with thin melanomas  Dermato-Onco2026 analysis supports the test's ability to provide individualized five-year recurrence-risk estimates in stage I–III melanoma FRIENDSWOOD, Texas, Nov. 11, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it will present new data on DecisionDx-Melanoma at the Society of Dermatology Physician Associates (SDPA) 24th Annual Fall Dermatology Conference, taking place Nov. 11-15, 2026, in Hollywood, Florida, and the 3rd European Congress on Dermato-Oncology (Dermato-Onco2026), taking place Nov. 12-13, 2026, in Rotterdam, The Netherlands. More precise assessment of a patient's risk of melanoma recurrence or death can help clinicians tailor follow-up and surveillance to each patient's individual needs.

news source

PRNewsWire • Nov 11, 2026

news preview

Castle Biosciences to Present at the Piper Sandler 38th Annual Healthcare Conference

FRIENDSWOOD, Texas, Nov. 11, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Piper Sandler 38th Annual Healthcare Conference on Wednesday, Dec. 2, 2026, at 8:10 a.m. Eastern time.

news source

PRNewsWire • Nov 11, 2026

news preview

Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 37%: Here's is How to Trade

The consensus price target hints at a 37% upside potential for Castle Biosciences (CSTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

news source

Zacks Investment Research • Nov 10, 2026

news preview

What Castle Biosciences (CSTL) Said on Its Q3 Earnings Call

Castle Biosciences NASDAQ: CSTL raised its full-year revenue outlook after reporting 24% third-quarter revenue growth, driven primarily by demand for its TissueCypher test.

news source

MarketBeat • Nov 6, 2026

news preview

Castle Biosciences, Inc. (CSTL) Q3 2026 Earnings Call Transcript

Castle Biosciences, Inc. (CSTL) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 6, 2026

news preview

Castle Biosciences Reports Third Quarter 2026 Results

Delivered Q3 2026 revenue of $102.9 million, an increase of 24% over Q3 2025 TissueCypher ® test report volume increased 47% over Q3 2025 Raising full-year 2026 revenue guidance to $385-395 million from $365-375 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Nov. 5, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended September 30, 2026.

news source

PRNewsWire • Nov 5, 2026

news preview

Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Beats Revenue Estimates

Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.02 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Castle Biosciences to Participate in Upcoming Investor Conferences

FRIENDSWOOD, Texas, Oct. 28, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Stephens Annual Investment Conference on Wednesday, Nov. 18, 2026, at 12:30 p.m. Central time.

news source

PRNewsWire • Oct 28, 2026

news preview

Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026

FRIENDSWOOD, Texas, Oct. 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2026, after the close of market on Thursday, Nov. 5, 2026.

news source

PRNewsWire • Oct 15, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Castle Biosciences, Inc.

Open an M1 investment account to buy and sell Castle Biosciences, Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in CSTL on M1